Study examines drug resistance in ALK positive lung cancer
AURORA, Colo. – Scientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) becomes resistant to a drug targeting the abnormal protein in the cancer. It’s the first time scientists have analyzed the frequency and type of drug resistance in ALK positive patients taking crizotinib.
Crizotinib, a tablet, shrinks tumors in the majority of ALK positive patients with dramatic responses in more than 60 percent of cases. The responses last approximately 48 weeks because the cancer eventually becomes resistant.
A study published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR), reveals ALK positive lung cancer mutates in two main ways. The cancer changes the ALK protein so that the crizotinib is ineffective against it or it develops another type of cancer molecule that makes the cancer less dependent on ALK. If the ALK protein changes, it may be vulnerable to a stronger ALK inhibitor. If it combines with another type of cancer molecule, a combination of drugs may be effective.
“We know that crizotinib brings ALK positive lung cancer under control for most patients. We wanted to learn how the cancer mutates so we can better treat it once it returns,” said Robert Doebele (see photo), MD, PhD, lead author of the study and CU Cancer Center investigator. “The mutations we documented show us once again that we can’t treat cancer as one disease. Cancer is as individual as our patients.”
The study was done at the CU Cancer Center and the University of Colorado School of Medicine.
“We are leading the way in the molecular testing of lung cancer. The testing helps us tailor individual treatments to specific sub-types of the disease” said Cancer Center investigator D. Ross Camidge, MD, PhD, director of the thoracic oncology clinical program at University of Colorado Hospital (UCH). “As the cancer changes, we have to change the way we attack it.”
The study was supported by grants from the Boettcher Foundation, Eli Lilly and Company and University of Colorado’s Lung Cancer Specialized Program of Research Excellence (SPORE).
The CU Cancer Center’s Thoracic Oncology Program is world renowned for its pioneering treatment of lung cancer. The program includes a multidisciplinary team of specialists and subspecialists working together to establish the best treatment plan for each patient. Advanced molecular profiling of a patient’s tumor, combined with an extensive array of standard and experimental treatments available through clinical trials has led to major advances in patient outcomes in the last few years. The program’s one-year survival rates for advanced lung cancer consistently run twice as high as the national average. The survival rates at five years run four times higher than the national average.
CU Cancer Center is the lead site for the national Lung Cancer Mutation Consortium, the collaboration of 14 of the nation’s elite lung cancer programs. The consortium is profiling 10 different molecular abnormalities in lung cancer and pairing them with specific experimental treatments over the next few years.
Please consider supporting the Lung Cancer Colorado Fund. This unique fund is overseen by the physicians and scientists and supports all aspects of the Center’s and University of Colorado Hospital’s combined fight against lung cancer.
For an appointment with a University of Colorado physician, please call Bethie Jean-Philippe, intake coordinator for the lung cancer program at 720-848-3386 or email [email protected]. To request physician interviews, please call Erika Matich at 303-524-2780 or email [email protected].